Single-course in vivo base editing therapy proven to lower cholesterol
Drug Discovery World
NOVEMBER 14, 2023
A Phase Ib trial has shown low-density lipoprotein cholesterol (LDL-C) reductions up to 55% and blood PCSK9 protein reductions up to 84% after a single infusion of Verve Therapeutics’ Verve-101. The two patients treated with 0.45mg/kg had a time-averaged blood PCSK9 protein reduction of 59% and 84%.
Let's personalize your content